SCHEMBL19283072

SCHEMBL19283072

O=c1[nH]nc(-c2ccc(OC(F)F)cc2)cc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.41
PDE4A P27815 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
PDE3B Q13370 2/20 0.41
PDE3A Q14432 2/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 2/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
GSK3A P49840 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19283081 0.80 PDE4A (0.69) MAPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL29892342 0.80 PDE4A (0.69) MAPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL1346306 0.80 SNCA (0.47) TP53PRMT5WDR77MAPTADORA3
SCHEMBL11152782 0.78 ADORA3 (0.56) MAPK1HPGDTP53CYP1A2CYP2C9
SCHEMBL10782022 0.77 LMNA (0.64) MAPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL20471653 0.74 ALPL (0.51) LMNAHPGDSMN1; SMN2GSK3AGSK3B
SCHEMBL1853118 0.74 MAPT (0.41) MAPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL19283074 0.73 PDE4A (0.62) MAPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL7369722 0.65 LMNA (0.59) MAPK1PDE4APDE4BPDE4CPDE4D
SCHEMBL20471405 0.64 DHODH (0.54) LMNASMN1; SMN2MAPTSCN5AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170247335-A1 FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2017-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247335-A1 FLUORINATED PYRIDAZIN-3-ONES FOR THE USE THEREOF IN THE TREATMENT OF LUNG DISEASES PEX3, NCOA3, NCAPD3 MAPK1 4125/4885PDE4A 2836/4885PDE4B 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.